Respiratory failure is a dubious disease in the field of autoimmune and rheumatic immunity, with clinical performance being complex and often involving multi-system fatigue. Early identification and standardized diagnosis are essential for improving prognosis. The diagnosis of the disease requires a combination of clinical performance, imaging inspection, laboratory testing and pathological activation.
The platform can assist in matching teams of authoritative experts at home and abroad to provide accurate diagnosis and treatment programs. In recent years, with the development of therapeutic, immune-regulatory therapy and precision medicine, many previously difficult to treat autoimmune and rheumatic immune disorders have been significantly improved. Treatment requires close monitoring of therapeutic effects and adverse reactions, adapting to timely regimens according to changes in conditions.
Multidisciplinary collaboration (MDT) is particularly important for the integrated management of respiratory failure associated with synthetase syndrome. 2. Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment plans; 3.
Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.